```html

Meningioma – Comprehensive Medical Guide

Overview

Meningioma is a tumor that arises from the meninges, the protective membranes covering the brain and spinal cord. Most meningiomas are benign (non‑cancerous) and grow slowly, but a small percentage are atypical or malignant and can behave more aggressively.

Key points:

• Incidence: Approximately 8 – 9 cases per 100,000 people each year in the United States, making meningioma the most common primary brain tumor in adults (CDC).
• Gender: Women are about twice as likely to develop meningioma as men, likely due to hormonal influences.
• Age: Most are diagnosed between ages 40 and 70; incidence rises sharply after age 50.
• Location: Over 80 % occur in the intracranial compartment; the remainder arise in the spinal canal.

Symptoms

Because meningiomas grow slowly, many are discovered incidentally on imaging done for another reason. When symptoms do appear, they reflect the tumor’s size, location, and the structures it compresses.

General (non‑specific) symptoms

• Headache: Typically dull and persistent; may worsen with coughing or straining.
• Seizures: Focal seizures are common, especially with tumors near the cerebral cortex.
• Fatigue or a feeling of “brain fog.”

Symptoms by location

• Frontal lobe meningioma: Personality changes, difficulty concentrating, depression, or impaired judgment.
• Temporal lobe: Memory problems, aphasia (difficulty speaking or understanding language), hearing loss.
• Parietal lobe: Loss of sensation or coordination on the opposite side of the body, visual field cuts.
• Occipital lobe: Visual disturbances such as blurred vision, double vision, or loss of peripheral vision.
• Posterior fossa (cerebellar) meningioma: Balance problems, unsteady gait, nausea, or vomiting.
• Skull‑base meningioma (e.g., near the optic nerve or cranial nerves): Double vision, loss of eye movement, facial numbness, hearing loss, or difficulty swallowing.
• Spinal meningioma: Neck or back pain, weakness or numbness in the arms or legs, difficulty walking, or urinary urgency.

Causes and Risk Factors

Most meningiomas have no single identifiable cause, but several factors increase risk:

• Genetic mutations: Alterations in the NF2 gene (neurofibromatosis type 2) are a well‑established cause; people with NF2 develop multiple meningiomas more often (Mayo Clinic).
• Radiation exposure: Prior therapeutic radiation to the head (e.g., for childhood cancers) raises the lifetime risk by 4‑ to 10‑fold.
• Hormonal factors: Female predominance suggests estrogen and progesterone may promote growth; some tumors express hormone receptors.
• Age: Risk increases with advancing age.
• Obesity: Higher body‑mass index correlates with a modestly increased risk (Cleveland Clinic).
• Family history: Rare familial clustering suggests inherited susceptibility in a minority of cases.

Diagnosis

A definitive diagnosis requires imaging and, in most cases, a tissue sample.

Imaging studies

• Magnetic Resonance Imaging (MRI): Gold‑standard. Gadolinium‑enhanced MRI shows a well‑defined, extra‑axial mass that “drapes” over the brain surface. T2‑weighted images help assess edema.
• Computed Tomography (CT): Useful for assessing calcifications and bone involvement, especially in skull‑base tumors.
• Positron Emission Tomography (PET): Occasionally used to differentiate high‑grade from low‑grade meningioma.

Biopsy / Surgical pathology

If imaging is ambiguous or if the tumor appears atypical, neurosurgeons obtain a tissue sample during resection. Pathology grades the tumor (I‑III) according to the WHO classification.

Additional tests

• Neuro‑ophthalmologic exam (for tumors near the optic nerve).
• Neuropsychological testing (to evaluate cognitive changes).
• Baseline blood work before surgery or radiation.

Treatment Options

Management depends on tumor size, location, grade, symptoms, patient age, and overall health.

Active surveillance (watchful waiting)

• Appropriate for small (<3 cm), asymptomatic, low‑grade tumors.
• Regular MRI (typically every 6–12 months) monitors growth.

Surgical removal

• Goal: Gross‑total resection (complete removal) when safely possible.
• Approaches vary: craniotomy, endoscopic endonasal, or minimally invasive keyhole techniques.
• Complication risk depends on location; skull‑base tumors have higher morbidity.

Radiation therapy

• External beam radiation (EBRT) / Stereotactic radiosurgery (SRS): Used when surgery is risky, after subtotal resection, or for recurrent tumors.
• Typical doses: 12‑16 Gy in one or few fractions for SRS (e.g., Gamma Knife, CyberKnife).

Pharmacologic treatment

• Hormonal therapy: Limited evidence; agents like mifepristone have been explored because some meningiomas express progesterone receptors.
• Targeted therapy: Clinical trials are evaluating VEGF inhibitors (e.g., bevacizumab) and tyrosine‑kinase inhibitors for refractory cases.
• Standard chemotherapy has not shown consistent benefit for typical meningiomas.

Supportive and lifestyle measures

• Anti‑seizure medications for patients with seizures.
• Analgesics or steroids to reduce peritumoral edema and headache.
• Physical and occupational therapy after surgery to restore function.

Living with Meningioma

Even after successful treatment, many patients need ongoing care and lifestyle adjustments.

• Follow‑up imaging: At least annually for the first 5 years, then spaced out if stable.
• Neuro‑cognitive monitoring: Memory or concentration problems may improve with rehab; consider a neuropsychology referral.
• Seizure management: Continue anti‑epileptic drugs as prescribed; avoid abrupt discontinuation.
• Fatigue management: Prioritize rest, regular light exercise, and balanced nutrition.
• Emotional health: Join support groups (e.g., American Brain Tumor Association) and discuss anxiety or depression with a mental‑health professional.

Prevention

Because most meningiomas are not linked to modifiable causes, true primary prevention is limited. However, risk reduction strategies include:

• Avoid unnecessary head radiation; discuss alternative imaging (e.g., MRI instead of CT) when possible.
• Maintain a healthy weight and exercise regularly; obesity is a modest risk factor.
• Women on long‑term hormone replacement therapy should discuss risks with their physician.
• For individuals with neurofibromatosis type 2 or a strong family history, engage in regular screening MRI as advised by a genetics specialist.

Complications

If left untreated or if treatment fails, meningiomas can lead to serious complications:

• Neurologic deficits: Permanent weakness, vision loss, or speech impairment due to irreversible brain tissue damage.
• Hydrocephalus: Tumor blockage of cerebrospinal fluid pathways, causing increased intracranial pressure.
• Seizure disorders: Chronic epilepsy may develop, especially after cortical involvement.
• Hormonal disturbances: Tumors near the pituitary gland can affect hormone production.
• Recurrence: Up to 20 % of completely resected low‑grade meningiomas recur within 10 years; higher grades recur more often.
• Rare malignant transformation: Atypical (WHO grade II) or anaplastic (grade III) meningiomas can behave like aggressive brain cancers.

When to Seek Emergency Care

Sources: Mayo Clinic, CDC Brain Tumor Fact Sheet, NIH National Cancer Institute, WHO Classification of Tumors of the Central Nervous System, Cleveland Clinic, American Brain Tumor Association, peer‑reviewed literature (e.g., J Neurosurg 2022; 136:123‑136).

```